As of September 30, 2026, Envoy Medical, Inc. carries a market capitalization of 52.58M, placing it among publicly traded companies globally. Its enterprise value stands at 38.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 52.58M |
| Enterprise Value | 38.78M |
Envoy Medical, Inc.'s next confirmed earnings release is scheduled for April 6, 2027.
| Earnings Date | 4/6/2027 |
As of September 30, 2026, Envoy Medical, Inc. has 7.72M shares outstanding.
| Shares Outstanding | 7.72M |
These figures are as of September 30, 2026. The price-to-sales ratio is 225.75, and the price-to-book ratio stands at -46.12.
| PS Ratio | 225.75 |
| PB Ratio | -46.12 |
| P/TBV Ratio | -46.12 |
| P/FCF Ratio | -2.32 |
| P/OCF Ratio | -2.35 |
These figures are as of September 30, 2026. The EV/Sales ratio of 167.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 38.78M versus a market cap of 52.58M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 167.90 |
As of September 30, 2026, Envoy Medical, Inc. maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.21 |
| Quick Ratio | 1.03 |
| Debt / Equity | -68.16 |
| Debt / EBITDA | -0.03 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -152.54, reflecting losses generated across the asset base. The company generates approximately 5,372.09 in revenue per employee across its workforce of 43.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.66 indicates how many times Envoy Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -152.54 |
| Revenue Per Employee | 5,372.09 |
| Employee Count | 43.00 |
| Inventory Turnover | 0.66 |
As of the close on November 16, 2026, Envoy Medical, Inc.'s stock has gained approximately 3.61% over the past 52 weeks. The 50-day moving average sits at 6.79, while the 200-day moving average is 6.88.
| 52-Week Price Change | 3.61% |
| 50-Day Moving Average | 6.79 |
| 200-Day Moving Average | 6.88 |
Over the twelve months ended September 30, 2026, Envoy Medical, Inc. generated 231,000.00 in revenue and converted that into -20.85M in net income, yielding earnings per share of -2.72. EBITDA reached -23.15M, while operating income came in at -23.45M.
| Revenue | 231,000.00 |
| Gross Profit | -815,000.00 |
| Operating Income | -23.45M |
| Pretax Income | -20.85M |
| Net Income | -20.85M |
| EBITDA | -23.15M |
| EBIT | -23.45M |
| Earnings Per Share (EPS) | -2.72 |
As of September 30, 2026, Envoy Medical, Inc. holds 14.57M in cash and equivalents against 777,000.00 in total debt, resulting in a net debt position of -14.57M. Total book value stands at -1.14M, with working capital of 2.99M providing operational flexibility.
| Cash & Cash Equivalents | 14.57M |
| Total Debt | 777,000.00 |
| Net Debt | -14.57M |
| Equity (Book Value) | -1.14M |
| Book Value Per Share | -0.15 |
| Working Capital | 2.99M |
Envoy Medical, Inc. produced -22.23M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -205,000.00 in capital expenditures, free cash flow totaled -22.44M - equivalent to -2.93 per share.
| Operating Cash Flow | -22.23M |
| Capital Expenditures | -205,000.00 |
| Free Cash Flow | -22.44M |
| FCF Per Share | -2.93 |
Over the twelve months ended September 30, 2026, Envoy Medical, Inc. posted a gross margin of -352.81, reflecting its pricing power and cost economics. The operating margin of -10,151.52 and net profit margin of -9,026.41 provide insight into operational efficiency.
| Gross Margin | -352.81 |
| Operating Margin | -10,151.52 |
| Pretax Margin | -9,026.41 |
| Profit Margin | -9,026.41 |
| EBITDA Margin | -10,020.78 |
Over the twelve months ended September 30, 2026, Envoy Medical, Inc. paid dividends of 0.00 per share. The dividend payout ratio of 19.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -43.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -63.63, meaning Envoy Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Payout Ratio | 19.65 |
| Shareholder Yield | -63.63 |
| FCF Yield | -43.03 |
Envoy Medical, Inc.'s most recent stock split took place on October 26, 2026 with a 10:1 split ratio.
| Last Split Date | 10/26/2026 |
| Split Ratio | 10:1 |
As of September 30, 2026, Envoy Medical, Inc. has an Altman Z-Score of -26.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.52 |